BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 33585182)

  • 1. Novel Combination Therapies for the Treatment of Bladder Cancer.
    Peng M; Xiao D; Bu Y; Long J; Yang X; Lv S; Yang X
    Front Oncol; 2020; 10():539527. PubMed ID: 33585182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targetable Pathways in Advanced Bladder Cancer: FGFR Signaling.
    Xiao JF; Caliri AW; Duex JE; Theodorescu D
    Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Erdafitinib for the treatment of metastatic bladder cancer.
    Montazeri K; Bellmunt J
    Expert Rev Clin Pharmacol; 2020 Jan; 13(1):1-6. PubMed ID: 31810398
    [No Abstract]   [Full Text] [Related]  

  • 4. Targeted therapies for advanced bladder cancer: new strategies with FGFR inhibitors.
    Casadei C; Dizman N; Schepisi G; Cursano MC; Basso U; Santini D; Pal SK; De Giorgi U
    Ther Adv Med Oncol; 2019; 11():1758835919890285. PubMed ID: 31803255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The future of bladder cancer therapy: Optimizing the inhibition of the fibroblast growth factor receptor.
    Morales-Barrera R; Suárez C; González M; Valverde C; Serra E; Mateo J; Raventos C; Maldonado X; Morote J; Carles J
    Cancer Treat Rev; 2020 Jun; 86():102000. PubMed ID: 32203842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder.
    Roskoski R
    Pharmacol Res; 2020 Jan; 151():104567. PubMed ID: 31770593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Erdafitinib for the treatment of urothelial cancer.
    Marandino L; Raggi D; Giannatempo P; Farè E; Necchi A
    Expert Rev Anticancer Ther; 2019 Oct; 19(10):835-846. PubMed ID: 31544541
    [No Abstract]   [Full Text] [Related]  

  • 8. Role of Targeted Therapies in Management of Metastatic Urothelial Cancer in the Era of Immunotherapy.
    Grivas P; Yu EY
    Curr Treat Options Oncol; 2019 Jun; 20(8):67. PubMed ID: 31254108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted therapies in bladder cancer: signaling pathways, applications, and challenges.
    Peng M; Chu X; Peng Y; Li D; Zhang Z; Wang W; Zhou X; Xiao D; Yang X
    MedComm (2020); 2023 Dec; 4(6):e455. PubMed ID: 38107059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of immunotherapy in bladder cancer: present and future on targeting PD(L)1 and CTLA-4 pathways.
    Rouanne M; Roumiguié M; Houédé N; Masson-Lecomte A; Colin P; Pignot G; Larré S; Xylinas E; Rouprêt M; Neuzillet Y
    World J Urol; 2018 Nov; 36(11):1727-1740. PubMed ID: 29855698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Angiopoietin-2 and TIE Pathway as a Therapeutic Target for Enhancing Antiangiogenic Therapy and Immunotherapy in Patients with Advanced Cancer.
    Leong A; Kim M
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33217955
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic implications of fibroblast growth factor receptor inhibitors in a combination regimen for solid tumors.
    Luo H; Zhang T; Cheng P; Li D; Ogorodniitchouk O; Lahmamssi C; Wang G; Lan M
    Oncol Lett; 2020 Sep; 20(3):2525-2536. PubMed ID: 32782571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer immunotherapy: new applications in urologic oncology.
    Hurwitz ME; Sokhn J; Petrylak DP
    Curr Opin Urol; 2016 Nov; 26(6):535-42. PubMed ID: 27584025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Future of immune checkpoint inhibitors: focus on tumor immune microenvironment.
    Jia Y; Liu L; Shan B
    Ann Transl Med; 2020 Sep; 8(17):1095. PubMed ID: 33145314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune checkpoint inhibitor combinations: Current efforts and important aspects for success.
    Kon E; Benhar I
    Drug Resist Updat; 2019 Jul; 45():13-29. PubMed ID: 31382144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bladder cancer, a unique model to understand cancer immunity and develop immunotherapy approaches.
    Song D; Powles T; Shi L; Zhang L; Ingersoll MA; Lu YJ
    J Pathol; 2019 Oct; 249(2):151-165. PubMed ID: 31102277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging role of checkpoint inhibition in localized bladder cancer.
    Singh P; Black P
    Urol Oncol; 2016 Dec; 34(12):548-555. PubMed ID: 27776977
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Androgen receptor in bladder cancer: A promising therapeutic target.
    Tripathi A; Gupta S
    Asian J Urol; 2020 Jul; 7(3):284-290. PubMed ID: 32742928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune Checkpoint Inhibitors in Lung Cancer: Role of Biomarkers and Combination Therapies.
    Maung TZ; Ergin HE; Javed M; Inga EE; Khan S
    Cureus; 2020 May; 12(5):e8095. PubMed ID: 32542150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cabozantinib in Combination with Immunotherapy for Advanced Renal Cell Carcinoma and Urothelial Carcinoma: Rationale and Clinical Evidence.
    Bergerot P; Lamb P; Wang E; Pal SK
    Mol Cancer Ther; 2019 Dec; 18(12):2185-2193. PubMed ID: 31792125
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.